Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075891 · ClinicalTrials.gov registry record · Phase 4
Oracea Soolantra Association in Participants With Severe Rosacea
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 273
- Enrollment target
NCT03075891 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 273 participants.
The verdict
NCT03075891, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 273 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of severe Rosacea.
Interventions
- DRUG Ivermectin 1% cream
- DRUG Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
- OTHER Oral placebo capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03075891
The ClinicalTrials.gov registry entry for NCT03075891 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ivermectin 1% cream is the first listed.
NCT03075891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03075891 about?
NCT03075891 is a clinical study titled "Oracea Soolantra Association in Participants With Severe Rosacea". The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of severe Rosacea.
What is the current status of trial NCT03075891?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 273 participants. The study started on 2017-07-05. Estimated completion is 2018-02-08.
What interventions are being tested in trial NCT03075891?
The interventions under investigation include: Ivermectin 1% cream (DRUG), Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules (DRUG), Oral placebo capsules (OTHER).
Who is sponsoring clinical trial NCT03075891?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.